Table 2—

Lung function and subjective efficacy measures

Terbutaline run-inFormoterol periodSalbutamol periodTreatment differencep-value
FEV1 L2.62±0.812.71±0.832.59±0.850.12 (0.07–0.16)<0.0001
FVC L3.87±1.163.96±1.163.88±1.180.07 (0.02–0.13)<0.01
Morning PEF L·min−1363±101372±110358±11013.8 (10.0–17.6)<0.0001
Evening PEF L·min−1380±102386±109372±10913.7 (9.2–18.1)<0.0001
Night-time symptoms 0–30.57±0.530.49±0.550.56±0.560.07 (0.03–0.11)<0.001
Daytime symptoms 0–31.01±0.480.87±0.570.98±0.570.11 (0.07–0.26)<0.0001
Nocturnal awakenings due to asthma·week−10.83±1.290.71±1.441.06±1.620.36 (0.20–0.51)<0.0001
Inhalations·24 h−12.40±1.332.26±1.452.48±1.500.22 (0.11–0.34)<0.001
Symptom-free days per period2.4±4.05.8±7.74.8±6.91.1 (0.4–1.7)<0.001
VAS: “How fast benefit…”54.0±21.250.3±23.33.7 (–0.0–7.5)0.051
VAS: “How long benefit…”58.6±24.154.2±23.74.3 (0.3–9.0)0.067
VAS: “How well did it work…”62.0±23.053.7±24.28.3 (4.9–11.7)<0.0001
VAS: “Asthma in general…”64.1±22.557.1±22.46.9 (3.2–10.6)<0.001
  • Data are presented as mean±sd or mean (95% confidence interval). FEV1: forced expiratory volume in one second; FVC: forced vital capacity; PEF: peak expiratory flow; VAS: visual analogue scale (0–100 mm).